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A B S T R A C T
The survey summarizes in its ﬁrst part the current status of knowledge on the Congenital Disorders of Glycosylation
(CDG) with regard to their phenotypic spectrum, diagnostic and therapeutic strategies, and pathophysiology. It
documents the clinical and basic research activities, and eﬀorts to involve patients and their families. In the second part,
it tries to look into the future of CDG. More speciﬁc biomarkers are needed for fast CDG diagnosis and treatment
monitoring. Whole genome sequencing will play an increasingly important role in the molecular diagnosis of unsolved
CDG. Epigenetic defects are expected to join the rapidly expanding genetic and allelic heterogeneity of the CDG family.
Novel treatments are urgently needed particularly for PMM2-CDG, the most prevalent CDG. Patient services such as
apps should be developed e.g. to document the natural history and monitor treatment. Networking (EURO-CDG, the
European Reference Networks (MetabERN)) is an eﬃcient tool to disseminate knowledge and boost collaboration at all
levels. The ﬁnal goal is of course to improve the quality of life of the patients and their families.
1. Introduction
Approximately half of all proteins typically expressed in a cell un-
dergo glycosylation to achieve their full functionality. There are mainly
two categories of glycosylation: N-glycosylation and O-glycosylation.
N-glycans are linked to the amide group of asparagine, while O-glycans
are linked to the hydroxyl group of serine or threonine. The synthesis of
N-glycans proceeds in three stages: formation of nucleotide-linked su-
gars, assembly (in cytosol and ER), and processing (in the Golgi). The
synthesis of O-glycans does not involve processing, and occurs mainly
in the Golgi. Besides, there is also lipid glycosylation and synthesis of
glycosylphosphatidylinositol anchors. Congenital Disorders of
Glycosylation (CDG) are genetic defects in the synthesis and attachment
of glycoprotein and glycolipid glycans. Initially, mutations were found
in genes encoding glycosyltransferases, remodelling glycosidases, and
sugar nucleotide transporters, that are all known to have a direct role in
glycosylation. However, new forms of CDG have recently been identi-
ﬁed with defects in vesicular traﬃcking, pH homeostasis or Mn2+
homeostasis. Various approaches have been developed for the eﬃcient
diagnosis of these diverse types of CDG (see section 2.2 for more de-
tails). Since their ﬁrst clinical description in 1980, 105 types of CDG
have been identiﬁed, and that number keeps rising. Their clinical
spectrum is extremely broad, covers nearly all known phenotypes, and
comprises new phenotypes. Research into CDG received an enormous
boost since 1999 thanks to the consecutive, collaborative initiatives of
EUROGLYCAN and EUROGLYCANET, that were originally funded by
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the European Commission's Framework Programmes. In 2011, our
group (Berlin, Brussels, Heidelberg, Leuven, Lille (Villeneuve d’Ascq),
Madrid, Nijmegen, and Paris) has successfully replied to the E-Rare-2
Call for Proposals with the EURO-CDG project. Research in the context
of EURO-CDG has yielded improved diagnostic methodologies resulting
in the identiﬁcation of an increasing number of CDG, shortening of the
time to diagnosis, and CDG diagnosis in patients who remained ‘un-
solved’ for many years. In addition, cellular models have been used to
study the pathophysiology of disease and to identify molecular path-
ways that can be targeted for therapy. Within the network, more than
1300 CDG patients received a deﬁnite diagnosis (with PMM2-CDG re-
presenting 62% of the recorded patients, and 30 other CDG re-
presenting the remaining 38%).
Eﬀorts are now guided towards the development of therapeutic
approaches for PMM2-CDG, the most frequent CDG, but also for the
more rare CDG. The functional characterization of disease-causing
mutations in PMM2-CDG patients led to the identiﬁcation of pharma-
cological chaperones to rescue the folding of the mutant PMM2 en-
zyme. In parallel, oral D-galactose therapy has been shown to be ben-
eﬁcial in CDG with hypogalactosylation. We initiated a multicentre
clinical trial to characterize the eﬀects of D-galactose supplementation
in diﬀerent genetic conditions aﬀecting Golgi glycosylation, including
PGM1-CDG, TMEM165-CDG and SLC35A2-CDG. The European net-
work for research on CDG wants to build on its past achievements and is
committed to explore diﬀerent possibilities to improve treatment and
quality of life of the patients and their families. It will of course also
share eﬀorts to this aim with other researchers interested in CDG. Open,
international meetings, often in parallel with patients and parents
meetings, are meant to exchange experience and results, and to pro-
mote progress in CDG.
2. CDG at present
2.1. Phenotypic spectrum
Table 1 tabulates the known CDG (in alphabetical order) with the
main associated organ involvement and symptomatology. For a recent
general review on CDG and a selection of reviews on organ/tissue-
speciﬁc CDG and speciﬁc CDG/CDG groups see Jaeken and Morava
2016; Jaeken and Péanne 2017. The fact that ﬁve novel CDG have been
reported in the ﬁrst half of 2017 illustrates the rapid expansion of this
disease family: ATP6V1A-CDG (Van Damme et al., 2017), ATP6V1E1-
CDG (Van Damme et al., 2017), PIGC-CDG (Edvardson et al., 2017),
TRAPPC11-CDG (Matalonga et al., 2017), and OGT-CDG (Willems
et al., 2017). Also, a novel regulatory mutation has been presented,
with a defect in the PMM2 promoter (Cabezas et al., 2017). In recent
years, it has become clear that some CDG can present totally diﬀerent
phenotypes depending on the types of mutation. Striking examples are
PMM2-CDG (a dysmorphism-disability syndrome; polycystic kidney
disease with hyperinsulinemic hypoglycaemia; isolated tendency to
thrombosis), ALG9-CDG (a dysmorphism/neuro-hepato-renal syn-
drome; a skeletal phenotype with death in utero), EXT2-CDG (exo-
stoses; seizures-scoliosis-macrocephaly syndrome), PIGA-CDG (in-
tellectual disability and seizures without dysmorphism; ferro-cerebro-
cutaneous syndrome; Simpson-Golabi-Behmel syndrome type 2; early
onset epileptic encephalopathy with severe muscular hypotonia, dys-
morphism, multiple congenital anomalies and early death (MCAHS2)),
and POGLUT1-CDG (skin disease; muscular dystrophy). No defects have
yet been reported in many genes of the glycosylation machinery, as for
instance in the Golgi mannosidases (except MAN1B1), in MGAT1,
B4GAT1,…which have been candidate genes, right from the beginning.
We reckon that patients with defects in these genes are extremely rare
and highly underestimated, or may not survive until birth.
There is an increasing number of reports on adult features of CDG
such as PMM2-CDG (up to 67 years; Monin et al., 2014; Barone et al.,
2015), SRD5A3-CDG (up to 45 years; Kahrizi et al., 2011; Kara et al.,
2014; Wheeler et al., 2016), PGM3-CDG (up to 35 years; Sassi et al.,
2014; Zhang et al., 2014), a.o. This helps in answering the often asked
question of parents: what is the future of my child?
2.2. CDG frequency and registry
The standard test for the diagnosis of N-glycosylation disorders with
sialic acid deﬁciency is still isoelectrofocusing of serum transferrin (Tf
IEF), which is only N-glycosylated. A type 1 pattern (decreased tetra-
sialotransferrin, increased disialo- and asialotransferrin) points to an
assembly defect or a defect in the transfer to the peptide chain (CDG-I),
whilst a type 2 pattern (increase also of threesialo- and mono-
sialotransferrin) suggests a remodelling defect (CDG-II). Note that in
normal infants up to about 6 weeks, the serum transferrin bands are
slightly more intense than later on (looking like a mild type 2 pattern).
In case of a typical MPI-CDG or PMM2-CDG presentation, enzymatic
testing can be performed in leukocytes or ﬁbroblasts although it is more
cumbersome than direct mutation analysis of the MPI and PMM2 genes
respectively. In addition, we have evidence that false negative PMM2
measurements in ﬁbroblasts occur (G. Matthijs, E. Van Schaftingen and
co-workers, unpublished). Hence, we propose to sequence the PMM2
gene ﬁrst in all CDG type I cases. In the other cases with a type 1
pattern, there is a tendency to ﬁrst perform a targeted CDG panel
analysis, and when negative, whole genome/exome sequencing. Lipid-
linked oligosaccharide analysis (LLO) in ﬁbroblasts for type 1 is a
cumbersome and expensive test that not always provides accurate re-
sults (see below). In patients with a type 2 pattern, mass spectrometry
of transferrin glycans can ﬁrst be performed but this rarely yields a
speciﬁc pattern. Isoelectrofocusing of serum apolipoprotein C-III (which
is only O-glycosylated) can detect some O-glycosylation disorders. A
ﬂowchart summarizing the approach to obtain molecular diagnosis in
unsolved CDG is depicted in Fig. 1.
Since there is no worldwide CDG registry, information about fre-
quency is lacking. In order to ﬁll up this gap, in November 2016 the
diﬀerent laboratories in Europe oﬀering CDG diagnosis were asked to
ﬁll an informal excel table with (i) the actual number of patients for
each type of molecularly diagnosed CDG-I and CDG-II; (ii) and for the
types with less than 4 patients, the initials and nationality of the pa-
tients, to avoid double counting of patients with a very rare CDG that
could have been studied by more than one laboratory; and (iii) the
number of ‘unsolved’ patients (indicating: positive screening for ab-
normal glycans, negative targeted sequencing or negative exome re-
sults). Thus only the CDG with an abnormal transferrin IEF were in-
cluded in this study (for example not alpha-dystroglycanopathies).
The following laboratories accepted to share their data: Barcelona,
Catania, Heidelberg, Leuven, Lille, Lyon, Madrid, Nijmegen, Paris,
Porto, Prague and Tallinn. The number of molecularly diagnosed pa-
tients was 1350, distributed among 94% CDG-I and 6% CDG-II. Twenty-
two diﬀerent types of CDG-I and 15 of CDG-II were reported. Fig. 2
shows the distribution of the patients. As to CDG-I (Fig. 2A), PMM2-
CDG, as expected, was by far the most frequent (62%; n: 834). ALG6-
CDG was the second most frequent (8%; n: 101), followed by SRD5A3-
CDG (n: 43), ALG1-CDG (n: 41) and MPI-CDG (n: 36). Regarding CDG-II
(Fig. 2B), MANB1-CDG was the type with the largest number of patients
(n: 18), followed by COG7-CDG (n: 10). The diﬀerent COG deﬁciencies
(COG1-CDG COG4-CDG to COG8-CDG) together comprised 33 patients.
The distribution of some speciﬁc types was strikingly diﬀerent within
the diﬀerent laboratories. For example, almost all of the TMEM165-
CDG patients (n: 5/6) were reported by Leuven, the SRD5A3-CDG pa-
tients mainly by Nijmegen. Importantly, it is worth mentioning that
some patients may have been counted twice, as samples traveled ex-
tensively especially in the early days of genetic diagnostics.
Finally, the number of reported molecularly unsolved cases was
relatively small (less than 100). The total number of diagnosed CDG
patients in Europe might reasonably exceed 2500 when adding those
from the United Kingdom, Ireland, and the countries of Northern and
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Table 1
Overview of CDG organ involvement and symptoms/signs Items before the semicolon are clinical symptoms and signs, and the items
after the semicolon are results of paraclinical investigations.
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Eastern Europe. The prevalence of CDG in Europe could then approach
0.1–0.5/100,000, which is far from the one of only PMM2-CDG calcu-
lated on the basis of carrier frequencies (1/20 000; Schollen et al.,
2000, 1/77 000; Vals et al., 2017). Thus, CDG is still largely under-
diagnosed, even in Europe, the most active region with regard to CDG
screening worldwide. This under-diagnosis leads to under-treatment
since some CDG are treatable, in particular MPI-CDG (mannose; de
Lonlay et al., 2001), and PGM1-CDG and SLC35A2-CDG (galactose;
Morava, 2014; Dörre et al., 2015).
The number of molecularly unsolved CDG patients (after exclusion
of galactosemia and fructosemia, see section 2.3 for more details) de-
creases thanks to targeted and whole exome sequencing. As expected,
CDG-I appeared to be much more frequent than CDG-II. This is logical
since 30 of the known 105 CDG show a Tf IEF type 1 pattern, while only
18 CDG show a type 2 pattern (48 in total; review in Jaeken and
Péanne, 2017). Thus only about half of the known CDG are picked up
by this test. Among these 48 CDG, eleven did not show up in this survey
performed by our network.
In conclusion, these preparatory results on CDG frequency will be a
helpful tool in accompanying the development of new therapeutics for
CDG patients and should be followed by setting up a patient register
containing full clinical and biological data.
2.3. Treatment
2.3.1. Therapeutic trials in cells
An important pitfall in the ﬁeld of many inherited metabolic dis-
orders is the lack of good cellular models for testing therapeutic drugs.
The cells most commonly used are patient-derived ﬁbroblasts. However
in diseases such as CDG these cells are not representative for the cells
that are involved in CDG pathophysiology. Furthermore, for testing
mutation-speciﬁc therapies cellular models are needed with speciﬁc
mutations. Recently, the generation of induced pluripotent stem cells
(iPSCs) and the number of reports on its applications have rapidly in-
creased because these cells provide a unique platform to carry out in
vitro drug screening tests (Thiesler et al., 2016). Nevertheless, the
generation of a battery of iPSCs bearing diﬀerent mutations for suc-
cessful therapeutic evaluation is a complex task. This prompted B. Pérez
and coworkers to develop other cellular models. They have generated a
biobank of patient-derived ﬁbroblasts overexpressing hypomorphic
mutant alleles. This cellular model allows a rapid screening of potential
drugs to be selected for further evaluation in neurons or hepatocytes
derived from iPSCs and, in the last step, for evaluation in animal models
(unpublished results). In addition, methodologies to generate knock-out
cell lines for speciﬁc gene defects have been established within the
EURO-CDG network, including Hap1, HEK293 and C2C12 cells.
Fig. 1. Updated diagnostic ﬂowchart for unsolved CDG.
IEF: isoelectrofocusing; NGS: next generation sequencing
(CDG panel, exome or genome sequencing). #: we re-
commend to perform serum transferrin IEF twice, using
independent serum samples.
Fig. 2. Distribution among twelve European la-
boratories of (A) CDG-I patients, and (B) CDG-II
patients. For more clarity, only the CDG-I with a
frequency higher than 3% (left panel) or the
CDG-II with a frequency higher than 5% (right
panel) are displayed.
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2.3.2. Treatment strategies in patients
MPI-CDG was the ﬁrst CDG with a fairly eﬀective treatment. Initial
studies showed signiﬁcant clinical improvement on dietary intervention
with oral mannose (1 g/kg per day divided in 3–4 doses), improving the
serum transferrin isoform pattern, coagulation anomalies, hyper-
insulinism and the protein losing enteropathy. Mannose therapy acts by
its transformation into mannose-6-phosphate, thus restoring the de-
fective pathway. Some patients require higher doses and a few patients
do not tolerate mannose due to recurrent hemolysis. Although mannose
reduces serum transaminase levels, it does not cure the liver disease in
MPI-CDG. Several MPI-CDG patients are known with progressive liver
cirrhosis and liver failure on mannose therapy. Liver transplantation
has been shown to be beneﬁcial in a few patients with full clinical re-
covery (Janssen et al., 2014).
PGM1-CDG involves several metabolic pathways, including glyco-
genolysis, glycolysis and glycosylation. Galactose therapy has been in-
troduced based on the hypogalactosylation pattern of protein glycans in
this disorder. It improves the mixed type of N-glycosylation defect.
While the Tf IEF type 2 pattern normalizes quickly, a full restoration is
rarely observed. Depending on the patient, dietary galactose in a dose
of 0.5–1.5 g/kg per day decreased serum transaminase levels and in-
creased coagulation factors, especially antithrombin. Some patients
showed better endocrine control, and a decrease in the frequency of
hypoglycemia and rhabdomyolysis. Muscle weakness and cardiomyo-
pathy seem to be unaﬀected by the galactose intervention in PGM1
deﬁciency. In a few patients uridine was added, but the eﬀect hereof is
not clear yet (Tegtmeyer et al., 2014; Morava, 2014; Wong et al., 2017).
CAD-CDG is a disorder in the pyrimidine biosynthesis, important for
glycosylation through its role in nucleotide biosynthesis. Both the se-
vere seizures and the microcytic anemia are treatable by oral uridine
supplements (Koch et al., 2017). Uridine is an eﬃcient treatment be-
cause it is a product of the defective pathway. Monosaccharide sup-
plementation is a partial treatment for individual patients in several
other N-glycosylation disorders. Oral galactose supplementation im-
proved seizures and a few blood parameters including Tf IEF in a subset
of SLC35A2-CDG patients (Dörre et al., 2015), and the bleeding dia-
thesis, endocrine function and Tf IEF in TMEM165-CDG (Morelle et al.,
2017). Both galactose and manganese improved the transferrin iso-
forms and the seizure disorder in SLC39A8-CDG (Park et al., 2015). The
treatment with mannose, galactose, manganese, and a possible treat-
ment with chaperones for PMM2-CDG is illustrated in Fig. 3. Oral fu-
cose treatment improved the immune disorder and decreased infection
frequency in a few patients with SLC35C1-CDG (Wild et al., 2002).
Besides in MPI-CDG, liver transplantation has also been performed
with partial success in CCDC115-CDG (Jansen et al., 2016a, 2016b).
Heart transplantation was successful in 2 children with mild DOLK-CDG
(Kapusta et al., 2013), and bone marrow transplantation led to im-
provement of the immune disease in PGM3-CDG (Stray-Pedersen et al.,
2014). Other potential therapeutic approaches aim at speciﬁc symp-
toms like hypoglycemia, hypothyroidism, pericarditis. Congenital
myasthenia such as in DPAGT1-CDG can be treated with cholinesterase
inhibitors (Finlayson et al., 2013).
2.4. Pathophysiology
A disordered glycosylation machinery does not only inﬂuence the
glycoprotein and glycolipid homeostasis, but can also have a signiﬁcant
secondary impact on other cellular pathways. The other way around,
some metabolic diseases such as galactosemia and fructose intolerance,
cause a secondary glycosylation disorder. They show a type 1 pattern.
Equally, alcoholism show a type 1 pattern while infections with neur-
aminidase-producing bacteria cause a type 2 pattern.
Although these hypoglycosylation devious side eﬀects were ex-
pected, they were somewhat out of the scope and began to gain center
stage just recently. First of course is the polyisoprenoid (or mevalonate)
pathway which is necessary for the synthesis of cholesterol and the
oligosaccharide lipid-carrier dolichol. Both are directly associated with
and inﬂuenced by the glycosylation process. A group of CDG, most
prominently exempliﬁed by the COG-related CDG, is secondary to
perturbation of the in- and outward vesicular traﬃcking at the Golgi
apparatus (Reynders et al., 2011). Since these transport processes play
central roles independent of protein glycosylation, the related disorders
are probably caused by a combination of protein hypoglycosylation and
defects in exo- and endocytosis, lysosomal function, and/or autophagy.
There is also a rising interest in pathways leading to the generation of
other metabolites such as aminoacids, acylcarnitines and lipids. In a
patient with ATP6AP1-CDG, dysregulated levels of several amino acids
(e.g. arginine) and strong up-regulated levels of acylcarnitines of the
long and very long species were found. Besides, within the main and
minor lipid classes reduced amounts of e.g. phosphatidylcholine in
combination with abnormalities of the plasmalogens were detected (C.
Thiel and co-workers, unpublished results).
It is worth mentioning that, as in CDG, defects in the metabolism of
amino acids and in the biosynthesis and remodelling of phospholipids,
sphingolipids and complex fatty acids can lead to pathology of the
nervous system and many other organs (de Koning, 2013; Lamari et al.,
Fig. 3. Schematic representation of some promising CDG treatments. Even if more treatments are being investigated (for instance for SLC35A2-CDG, CAD-CDG, SLC39A8-CDG or
SLC35A1-CDG), only the therapeutic approaches developed within the European EURO-CDG network are illustrated.
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2015). More metabolomic analyses of patient material as well as of CDG
animal models will help to further elucidate the role of glycosylation in
other pathways. This will be of major help in understanding the com-
plex pathophysiology underlying a glycosylation deﬁciency and in es-
tablishing new therapeutic approaches.
2.5. Patients and parents involvement
The parents have been very active in raising awareness for CDG and
in helping families. They have also contributed to the commitment of
the basic and clinical research community for CDG. At the risk of not
being comprehensive and forgetting to honour several organisations
that have been active in CDG – and the people that are the drivers
behind these associations - we want to name a few that have con-
tributed signiﬁcantly. First, there have been parents associations in
Denmark (Den Danske CDG Forening), in Germany (Glycokids®), in
Sweden (Svenska CDG-Föreningen) and later associations were founded
in Canada (Foundation Glycosylation (the FoG)), France (Les P'tits
CDG), the Netherlands (CDG Netherlands), Portugal (Associação
Portuguesa CDG, APCDG), Spain (AES CDG), and the UK (CDG UK),
who have been very active at the national level. Prior to these, the
American CDG Family Network Inc. has organized meetings in asso-
ciation with the EUROGLYCAN, EUROGLYCANET and EURO-CDG
networks, a.o. in Leuven (1999) and in Worms (2008).
In 2013, the Portuguese CDG Association has organised in Barcelona
the ﬁrst World Conference on CDG, a gather of patients, parents, policy
makers, representatives from industry and scientists. The second and
third World Conference took place in Lyon in 2015 and in Leuven in
2017, the latter again in conjunction with EURO-CDG. Reports and
videos of these gatherings are available (http://www.apcdg.com/).
Thanks to joint programs for parents, clinicians and basic scientists, a
strong impetus is given to research in the ﬁeld of CDG. A very inter-
esting leaﬂet providing general information on CDG to parents has been
developed by clinicians, scientists from the Barcelona Hospital Sant
Juan de Déu, together with the parents (see http://www.euroglycanet.
org/uz/digitalAssets/1006_P05-Barcelona-Triptico_CDG.pdf). Other in-
formation is available at the patients' and parents' association websites.
For information on ‘inclusive education’ see https://www.includ-ed.eu/
, http://aaate.net/ and https://www.european-agency.org/.
3. The future of CDG
3.1. Developments in the diagnostics of CDG: protein-speciﬁc glycoproﬁling
and metabolic labelling as functional diagnostic tools
About 50 genetic glycosylation defects are known that can be
screened for by Tf IEF (Jaeken and Péanne, 2017). The identiﬁcation of
novel types of CDG-I, with a defect in the cytosol or endoplasmic re-
ticulum (ER), has been very successful thanks to direct metabolic la-
beling of cultured CDG patients' cells with radioactive [2-(3H)] man-
nose (Péanne et al., 2013). Following lipid-linked oligosaccharide (LLO)
analysis, the culprit gene could relatively easily be identiﬁed thanks to
the high level of conservation of the N-glycosylation pathway in the ER
between humans and yeast. Next-generation sequencing, via whole-
exome sequencing or targeted gene panels, has replaced LLO analysis
for gene identiﬁcation. In combination with clinical phenotyping, an
eﬃcient diagnostic protocol for CDG-I subtyping has been achieved. For
identiﬁcation of CDG-II defects, glycan structural analysis by glycomics
has been instructive to deﬁne genetic defects, such as MGAT2-,
SLC35C1-, SLC35A1-, B4GALT1-and MAN1B1-CDG, that are directly
associated with enzymes and transporters involved in the Golgi pro-
cessing of glycans (Jaeken and Péanne, 2017). However, the newer
forms of CDG-II with defects in vesicular traﬃcking and ion home-
ostasis are clearly more diﬃcult to elucidate. The discovery of a CDG-II
patient with COG7 –deﬁciency increased the awareness of the impact of
abnormal traﬃcking on glycosylation in humans (Reynders et al., 2011;
Wu et al., 2004). Similarly, the identiﬁcation of mutations in the V-
ATPase complex (ATP6V0A2, ATP6V1E1, and ATP6V1A) and in V-A-
TPase assembly factors (ATP6AP1, CCDC115 and TMEM199) extended
the causes of CDG to intracellular compartmental pH defects (Jansen
et al., 2016a, 2016b; Kornak et al., 2008; Van Damme et al., 2017). This
is also true for defects in TMEM165 and SLC39A8, two genes that link
CDG to deﬁciency of the trace element manganese (Park et al., 2015;
Potelle et al., 2017). These observations suggest that any defect that
disturbs the function and organization of the Golgi complex may lead to
abnormal glycosylation and thus to CDG. As a result, the number of
candidate genes becomes very large. In the majority of cases, glycomics
proﬁling of total serum N-linked glycoproteins does not result in suf-
ﬁciently speciﬁc signatures to directly diagnose the respective CDG-II
defects. Since plasma biomarkers are highly relevant and easily acces-
sible for CDG diagnostics and subtyping, future eﬀorts will aim at the
development of proteome-wide analysis of glycopeptides to identify
protein-speciﬁc CDG biomarkers. For example, immunoglobulin gly-
cosylation was shown to be aﬀected in MOGS-CDG, while transferrin
remained unaﬀected (Sadat et al., 2014).
Exome sequencing has greatly facilitated the search for novel genes
and is now commonly used in CDG-II diagnostics. On the other hand,
disorders like EXT1-and EXT2-CDG, which are not captured by testing
for abnormal serum protein glycosylation, indicate that there may be
many more monogenic disorders with relevant tissue-speciﬁc glycosy-
lation deﬁciencies. The conﬁrmation of this kind of eﬀect of genetic
variants is highly challenging, due to the limited availability of easy
read-out systems for visualization and analysis of glycosylation deﬁ-
ciencies in patient material. The advent of bioorthogonal click chem-
istry with the emergence of metabolic oligosaccharide engineering
(MOE) has opened a completely new ﬁeld of investigation (Ovryn et al.,
2017). This extremely powerful strategy allows via a chemical reaction
to decipher in living cells a speciﬁc metabolic pathway without inter-
fering with it. The available chemical toolbox and the strategies to
study glycosylation in normal and pathophysiological conditions are
constantly growing. In the ﬁeld of CDG, the use of two unprotected
monosaccharide reporters, namely N-4-pentynoylneuraminic acid
(SiaNAl) and N-(4-pentynoyl) mannosamine (ManNAl) has proved to be
an eﬀective method to track glycoconjugate sialylation defects
(Vanbeselaere et al., 2013; Gilormini et al., 2016). Such labeling stra-
tegies, coupled to the use of diﬀerent azido functionalized ﬂuorescent
probes allowed to quantitatively measure the Golgi glycosylation eﬃ-
ciency in CDG patient cells. This assay was successfully applied in
COG-, TMEM165-, CCDC115- and TMEM199-CDG patient ﬁbroblasts
(Vanbeselaere et al., 2013; Jansen et al., 2016a, 2016b), showing a
drastically reduced incorporation of monosaccharide reporters, which
was restored upon complementation with wild-type gene. This novel
approach will be also facilitate the conﬁrmation of novel CDG-II defects
in Golgi homeostasis, as still many Golgi defects are expected to be
discovered.
3.2. Beyond genetics: epigenetic studies
Epigenomics or alterations to chromatin (modiﬁcations of DNA and
histones) can be divided in chromatin marks (individual chemical
modiﬁcations) and features (multiple linked modiﬁcations and more
complex elements). Examples of the ﬁrst are DNA methylations and
histone acetylations, and of the latter chromatin interactions, RNA
modiﬁcations and non-coding RNAs (reviewed in Stricker et al., 2017).
A large body of literature documents epigenetic regulation of glycosy-
lation, mostly by showing aberrant glycosylation in cancer. A change in
cytosine methylation within the promotor of certain glyco-genes is re-
sponsible for the expression of cancer-associated carbohydrate anti-
gens, in gastrointestinal, pancreatic and breast cancer. Other examples
of epigenetic regulation of glyco-genes include FUT7 in leukocytes and
the transcription factor HNF1A, a master regulator of plasma protein
fucosylation (Zoldoš et al., 2013; Lauc et al., 2014). Treatments of
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cultured cells with epigenetic inhibitors reveal that N-glycome proﬁles
drastically change, which indicates that many glycosylation-related
genes are regulated by DNA and histone modiﬁcations (Saldova et al.,
2011). To the best of our knowledge, there are no clear examples of
CDG caused by epigenetic changes, probably because we are not
looking for such defects. However, we are quite convinced that epige-
netic disorders will become an important CDG chapter.
3.3. In search for novel treatments
The functional characterization of phosphomannomutase 2 (PMM2)
disease-causing mutations has suggested that PMM2-CDG could be a
conformational disease and that therapies addressed to improve the
protein folding would be able to ameliorate the clinical symptoms
(Yuste-Checa et al., 2015). From a 10,000 compound library screening,
8 possible pharmacological chaperone (PCs) were selected. The com-
pound 1-(3-chlorophenyl)-3-3-bis(pyridine-2-yl)urea stood out, based
on its pharmacochemical properties, the absence of inhibitory eﬀect on
PMM enzymatic activity and the improved stability of a number of
destabilizing mutant proteins. PMM activity assays were performed
with soluble cell extracts from healthy and patient-derived ﬁbroblasts
overexpressing wild type PMM2 or PMM2 with the mutations p.As-
p65Tyr, p.Pro113Leu, p.Arg162Trp and p.Thr237Met. These results
have provided the ﬁrst proof-of-concept of a possible treatment for
PMM2-CDG and identiﬁed a promising chemical structure as a starting
lead for the development of therapeutic agents against this severe or-
phan disease (Yuste-Checa et al., 2017). Future clinical trials aim at D-
galactose use in diﬀerent CDG, liposomal mannose-1-phosphate and
chaperone therapy in PMM2-CDG (Fig. 2), and possibly PMM enzyme
replacement therapy. However, there are major hurdles for enzyme
replacement, because it is diﬃcult to target deﬁciencies in the cytosol,
the endoplasmic reticulum or the Golgi compartment. The ﬁnding that
GDP-mannose levels are tightly controlled by a feedback loop involving
GMPPA (Koehler et al., 2013) opens the possibility that PMM2 defects
could be treated by pharmacological intervention aimed at suppressing
the inhibition exerted by GMPPA on GMPPB, the catalytic subunit of
GDP-mannose pyrophosphorylase.
3.4. CDG reference network
MetabERN is a European non-proﬁt network established by the EU
to facilitate access to the best available care and to address the needs of
all European patients aﬀected by any rare inherited metabolic disease
(IMD) and their families. MetabERN already involves 69 specialized
metabolic centers from 19 countries and is continuously growing. It
aims to promote prevention, accelerate diagnosis and improve stan-
dards of care across Europe for patients with an IMD. It is entirely
patient- and expert-led. The 7 subnetworks focus on disorder groups,
one of which is disorders of glycosylation and intracellular traﬃcking.
This subnetwork aims at initiating natural history studies and ther-
apeutic trials in diﬀerent CDG.
3.5. eHealth at the service of the patient
Nanotechnology is invading daily life and this should proﬁt the
patients. The CDG patient community as well as the researchers in-
volved in CDG would beneﬁt from the development and use of speciﬁc
apps for the follow-up of patients. Indeed, CDG is characterized by
frequent and often severe clinical events throughout the life of the
patients. Examples are seizures, bleeding, infections, but also events
like hospitalisation, change of drug treatment, frequency of physical
therapy sessions, etc. A detailed, online registration would allow the
collection of data necessary for the natural history of the diﬀerent types
of CDG. A mobile tool would be especially welcome, given the extreme
genetic heterogeneity of CDG, the broad clinical spectrum and variable
symptoms, the rarity of most of the types of the disease and the large
geographical distribution of the patients. The diﬀerent compounds of
the app should be developed in collaboration with clinicians and pa-
tients' representatives, and the data collected in accordance with na-
tional and international laws on medical records and privacy. The app
should be useful to inform caretakers of critical events, and allow rapid
clinical action if needed (alert function).
4. Conclusion
CDG are a family of, largely not yet treatable, genetic diseases. Like
for all patients, it is of utmost importance to provide the best possible
care and support to these patients and their families. These include a
well-organized, multidisciplinary medical approach and follow-up,
optimal paramedical services (physiotherapy, speech therapy, social
service a.o.), regularly updated information (via meetings, letters, so-
cial media), and practical help e.g. by speciﬁc apps. The patients/fa-
milies, caregivers, and researchers should form a strong community at
the service of the patients. The EURO-CDG initiatives are prominent
examples of such collaboration and take the lead in this undertaking.
We hope that this survey may contribute to this goal.
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